Abstract:Serotonin (5-HT) receptors are proteins involved in various neurological and biological processes, such as aggression, anxiety, appetite, cognition, learning, memory, mood, sleep, and thermoregulation. They are commonly associated with drug abuse and addiction due to their importance as targets for various pharmaceutical and recreational drugs. However, due to a high sequence similarity/identity among 5-HT receptors and the unavailability of the 3D structure of the different 5-HT receptor, no report was available so far regarding the systematical comparison of the key and selective residues involved in the binding pocket, making it difficult to design subtype-selective serotonergic drugs. In this work, we first built and validated three-dimensional models for all 5-HT receptors based on the existing crystal structures of 5-HT1B, 5-HT2B, and 5-HT2C. Then, we performed molecular docking studies between 5-HT receptors agonists/inhibitors and our 3D models. The results from docking were consistent with the known binding affinities of each model. Sequentially, we compared the binding pose and selective residues among 5-HT receptors. Our results showed that the affinity variation could be potentially attributed to the selective residues located in the binding pockets. Moreover, we performed MD simulations for 12 5-HT receptors complexed with ligands; the results were consistent with our docking results and the reported data. Finally, we carried out off-target prediction and blood-brain barrier (BBB) prediction for Captagon using our established hallucinogen-related chemogenomics knowledgebase and in-house computational tools, with the hope to provide more information regarding the use of Captagon. We showed that 5-HT2C, 5-HT5A, and 5-HT7 were the most promising targets for Captagon before metabolism. Overall, our findings can provide insights into future drug discovery and design of medications with high specificity to the individual 5-HT receptor to decrease the risk of addiction and prevent drug abuse.

Insights into the discovery of new 5-HT1A receptor ligands:receptor based pharmacophore

Molecular Modeling of the 3D Structure of 5-HT(1A)R: Discovery of Novel 5-HT(1A)R Agonists Via Dynamic Pharmacophore-Based Virtual Screening.

Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis

Discovery of a Novel 5-HT2A inhibitor by pharmacophore-based virtual screening

Synthesis And Characterization Of 5-Hydroxy-2-(2-Phenylethyl)Chromone (5-Hpec) And Its Analogues As Non-Nitrogenous 5-Ht2b Ligands

Discovery and in vitro Evaluation of Novel Serotonin 5-HT2A Receptor Ligands Identified Through Virtual Screening

Identification of Novel TRPC5 Inhibitors by Pharmacophore-Based and Structure-Based Approaches

Higher-Affinity Agonists of 5-HT1AR Discovered Through Tuning the Binding-Site Flexibility

Discovery of Novel Indolealkylpiperazine Derivatives As Potent 5-HT1A Receptor Agonists for the Potential Future Treatment of Depression

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Molecular insights into the modulation of the 5HT2A receptor by serotonin, psilocin, and the G protein subunit Gqalpha

Multitarget-Directed Ligands Hitting Serotonin Receptors: A Medicinal Chemistry Survey

Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands

Design, Synthesis, and Structure-Activity Relationship Studies of Novel Indolyalkylpiperazine Derivatives as Selective 5-HT1A Receptor Agonists

Structure-based 3D-QSAR Studies on Thiazoles As 5-HT3 Receptor Antagonists

Molecular Modelling and Virtual Screening to Identify New Piperazine Derivatives as Potent Human 5-HT1A Antagonists and Reuptake Inhibitors

Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor

Design, synthesis, and biological evaluation of piperazine derivatives involved in the 5-HT1AR/BDNF/PKA pathway

Toll-like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies.

Pharmacological Relationships and Ligand Discovery of G Protein-Coupled Receptors Revealed by Simultaneous Ligand and Receptor Clustering.

Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study.